phe885
novartis
['multiple myeloma', 'phe885']
phase 1 trial of fully human, bcma car-t phe885 manufactured in &lt;2 days on the t-charge platform, presented by adam sperling, md, phd, ( ) at #asco23. data shows high response rates with no unexpected safety findings in patients with r/r multiple myeloma. 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090